Vemurafenib-Cediranib Combination Could Improve Response in Melanoma Patients

Source: Clinical Oncology News, November 2015

A combination of vemurafenib and cediranib might induce a complete response in some patients with vemurafenib-resistant BRAF-mutant melanoma, investigators at Massachusetts General Hospital, in Boston, have reported (PLoS One 2015;10[10]:e0140310, PMID: 26461489).

The team studied the effect of nearly 6,000 oncology drug combinations on 36 melanoma cell lines, and found that the combination of vemurafenib and cediranib effectively treated melanoma without leading to BRAF-inhibitor resistance.